VEGFR1 and VEGFR2 are induced in a tumor stage-dependent manner during glioma progression [22] and are exclusively expressed in tumor vascular endothelial cells [20, 23] and glioma cells [24, 25], suggesting that VEGF-receptors are promising targets for tumor endothelial cell specific therapy for glioma patients. The gene discussed is FLT1; the disease is neoplasm.